Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals PLC has purchased 423,072 of its ordinary shares on the London Stock Exchange between July 6th and July 10th, 2026, as part of its $250 million share repurchase program. The volume-weighted average price paid for these shares was 1,617.18 pence. These repurchased shares are intended for cancellation, and following their cancellation, the company will have 211,711,706 ordinary shares in issue.

Disclaimer*

UK 100

Latest directors dealings